Legend Biotech Corporation (LEGN)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Announces Presentations at ASCO 2026

Preliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to...

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

SOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

SOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities